Skip to main content
Article thumbnail
Location of Repository

Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection

By Juan C. Engel, Patricia S. Doyle, Ivy Hsieh and James H. McKerrow


Trypanosoma cruzi is the causative agent of Chagas' disease. The major protease, cruzain, is a target for the development of new chemotherapy. We report the first successful treatment of an animal model of Chagas' disease with inhibitors designed to inactivate cruzain. Treatment with fluoromethyl ketone–derivatized pseudopeptides rescued mice from lethal infection. The optimal pseudopeptide scaffold was phenylalanine-homophenylalanine. To achieve cure of infection, this pseudopeptide scaffold was incorporated in a less toxic vinyl sulfone derivative. N-methyl piperazine-Phe-homoPhe-vinyl sulfone phenyl also rescued mice from a lethal infection. Six of the treated mice survived over nine months, three without further treatment. Three mice that had entered the chronic stage of infection were retreated with a 20-d regimen. At the conclusion of the experiments, five of the six mice had repeated negative hemacultures, indicative of parasitological cure. Studies of the effect of inhibitors on the intracellular amastigote form suggest that the life cycle is interrupted because of inhibitor arrest of normal autoproteolytic cruzain processing at the level of the Golgi complex. Parasites recovered from the hearts of treated mice showed the same abnormalities as those treated in vitro. No abnormalities were noted in the Golgi complex of host cells. This study provides proof of concept that cysteine protease inhibitors can be given at therapeutic doses to animals to selectively arrest a parasitic infection

Topics: Articles
Publisher: The Rockefeller University Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1995). A cysteine protease is a target for the enzyme structure-based design of antiparasitic drugs. Drug Inf.
  2. (1993). American Trypanosomiasis (Chagas’ disease)—a tropical disease now in the United States. New Engl.
  3. Assessment of cytogenetic damage in chagasic children treated with benznidazole.
  4. (1997). Autoimmune rejection of neonatal heart transplants in experimental Chaga’s disease is a parasite-specific response to infected hosttissue.
  5. (1997). Cardiac involvement is a constant finding in acute Chagas’ disease: a clinical, parasitological and histopathological study.
  6. (1981). Carlos Chagas: Coletanea de trabalhos cientificos. Editora Universidade de Brasilia.
  7. (1996). Chagasic granulomatous encephalitis in immunosuppressed patients. Computed tomography and magnetic resonance imaging findings.
  8. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
  9. (1997). Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi.
  10. (1998). Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi.
  11. (1996). Cysteine proteases: evolution, function, and inhibitor design.
  12. (1985). Evaluation of chemotherapy with benznidazole and nifurtimox in734 Treatment of T. cruzi–infected Mice with Cysteine mice infected with Trypanosoma cruzi strains of different types.
  13. (1996). High resolution localization of cruzipain and Ssp4 in Trypanosoma cruzi by replica staining label fracture.
  14. (1970). Immunodiagnostico da doenca de Chagas. Evolucao serologica de pacientes com doenca de Chagas.
  15. (1992). Inhibitors of the major cysteinyl proteinase (GP57/51) impair host cell invasion and arrest the intracellular development of Trypanosoma cruzi in vitro.
  16. (1977). Intraspecific variation in Trypanosoma cruzi: effect of temperature on the intracellular differentiation in tissue culture.
  17. (1997). Isolation and quantification of fluoroacetate in rat tissues following dosing of Z-Phe-AlaCH2-F, a peptidyl fluoromethyl ketone protease inhibitor.
  18. (1990). Lysis of trypanosomes by peptidyl fluoromethyl ketones.
  19. (1996). Parasite cysteine proteinases.
  20. (1993). Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi.
  21. (1991). Post-cardiac transplant reactivation of Chagas’ disease diagnosed by skin biopsy.
  22. (1993). Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi.
  23. (1984). Redistribution of alpha-granules and their contents in thrombin-stimulated platelets.
  24. (1991). Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy.
  25. Structural and functional heterogeneity among peroxidase-negative granules in human neutrophils: identification of a distinct gelatinase-containing granule subset by combined immunocytochemistry and subcellular fractionation.
  26. (1993). Structurebased inhibitor design by using protein models for the development of antiparasitic agents.
  27. (1987). Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas’ disease.
  28. (1995). The crystal structure of cruzain: a therapeutic target for Chagas’ disease.
  29. (1995). The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design.
  30. (1968). The influence of environmental temperature on the pathogenicity of Trypanosoma cruzi in mice.
  31. (1996). The National Foundation of Brazil.
  32. (1998). The roles of cytochrome P450 3A and Pglycoprotein in the absorption, metabolism and elimination of a novel cysteine protease inhibitor.
  33. (1994). Treatment of chronic Chagas’ disease with benznidazole: clinical and serological evolution of patients with long-term follow up.
  34. (1990). Tropical diseases.
  35. (1996). Trypanosoma cruzi meningoencephalitis in AIDS mimicking cerebral metastasis: case report.
  36. (1994). Trypanosoma cruzi: identification of a membrane cysteine proteinase linked through a GPI anchor.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.